Although the combined use of BRAF and MEK inhibitors has shown a better effect in the clinical treatment of melanoma patients, some clinical adverse reactions are quite common in combination schemes, such as vomiting, nausea, fatigue, headache, arthralgia and so on [105]. The gene discussed is BRAF; the disease is melanoma.